Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Malignant Neoplastic Disease Clear all
Suspended Not applicable Interventional

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT07067138
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
Interventions
Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT), TruSight(R) Oncology 500, TruSeq Matched Tumor Normal Whole Exome Sequencing Assay
Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Terminated Phase 1 Interventional

A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

NCT05317078
View directory record Official record
Conditions
Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors
Interventions
AMG 794
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Orange, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jun 10, 2026, 2:10 PM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

NCT04957615
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions
Nivolumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Not applicable Interventional Results available

Ultrasound Elastography in Imaging Patients With Thyroid Nodules

NCT03174925
View directory record Official record
Conditions
Malignant Thyroid Gland Neoplasm, Thyroid Gland Nodule
Interventions
Siemens Acuson S3000 ultrasound system
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)

NCT03064490
View directory record Official record
Conditions
Locally Advanced Esophageal and Gastric Cancers (EGC)
Interventions
Pembrolizumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Jun 10, 2026, 2:10 PM EDT
Terminated Phase 2 Interventional Results available

Sunitinib to Treat Recurrent Brain Cancer

NCT00923117
View directory record Official record
Conditions
Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
Interventions
Sutent (sunitinib)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effectiveness of Direct-to-Patient Outreach on Colorectal Cancer Screening Within a Low Income and Diverse Population

NCT01385579
View directory record Official record
Conditions
Malignant Neoplasm of Large Intestine
Interventions
Care manager outreach
Other
Lead sponsor
Northwestern University
Other
Eligibility
50 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Jun 10, 2026, 2:10 PM EDT
Active, not recruiting Phase 3 Interventional

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

NCT06745024
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
Interventions
Best Practice, Biospecimen Collection, Bone Metastases Treatment, Computed Tomography, Conventional Radiotherapy, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Stereotactic Body Radiation Therapy
Other · Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
625
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 450 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Withdrawn Not applicable Interventional

Breast Reconstruction Following Breast Cancer in Very High Risk Patients

NCT03261323
View directory record Official record
Conditions
Breast Cancer, Malignant Neoplasm of Breast
Interventions
Immediate Breast Reconstruction, Delayed Breast Reconstruction, Breast-Q questionnaire
Procedure · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

NCT03207555
View directory record Official record
Conditions
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions
Ibrutinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jun 10, 2026, 2:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Use of an In Vivo Optical Probe to Discriminate Benign From Malignant Thyroid Nodules

NCT01401855
View directory record Official record
Conditions
Cancer, Thyroid
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma

NCT00003876
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
polifeprosan 20 with carmustine implant, surgical procedure, iodine I 125
Drug · Procedure · Radiation
Lead sponsor
Barrett Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery

NCT02540876
View directory record Official record
Conditions
Metastatic Malignant Neoplasm, Solid Neoplasm, Unresectable Malignant Neoplasm
Interventions
Ilorasertib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional

Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors

NCT00003574
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
surgical procedure, brachytherapy, intraoperative radiation therapy, iodine I 125
Procedure · Radiation
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors

NCT00002543
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gallium nitrate
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Jun 10, 2026, 2:10 PM EDT
Recruiting No phase listed Observational

AIMS Cancer Outcomes Study

NCT04495790
View directory record Official record
Conditions
Neoplasms, Neoplasm Malignant, Advanced Cancer, Advanced Solid Tumor, Oncology
Interventions
Not listed
Lead sponsor
Advanced Integrative Medical Science Institute
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jun 10, 2026, 2:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

NCT05468359
View directory record Official record
Conditions
Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor, Pediatric Cancer, Pediatric Solid Tumor, Fibrolamellar Carcinoma
Interventions
Atezolizumab, Sorafenib, Bevacizumab, Cyclophosphamide
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
2
States / cities
Germantown, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Recruiting Not applicable Interventional

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

NCT03683680
View directory record Official record
Conditions
Mesothelioma
Interventions
MPT Test, CLDN15/VIM Test
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Recruiting Not applicable Interventional

Characterization of Hyperpolarized Pyruvate MRI Reproducibility

NCT02421380
View directory record Official record
Conditions
Malignant Solid Tumors
Interventions
Hyperpolarized Pyruvate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 90 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Montvale, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 10, 2026, 2:10 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Parent and Family Oriented Support Interventions for the Facilitation of Weight Loss in African American Families

NCT04644224
View directory record Official record
Conditions
Obesity-Related Malignant Neoplasm
Interventions
Educational Activity, Educational Intervention, Informational Intervention, Questionnaire Administration, Support Group Therapy
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

ABT-751 in Treating Young Patients With Refractory Solid Tumors

NCT00036959
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ABT-751
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

NCT03433183
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1
Interventions
Selumetinib, Sirolimus
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Not yet recruiting No phase listed Observational

Clinical Genetics Branch Eligibility Screening Survey

NCT07005297
View directory record Official record
Conditions
Melanoma, Li-Fraumeni Syndrome, Pulmonary Blastoma, Chordoma, Congenital Bone Marrow Failure Syndromes, Costello Syndrome, Fanconi Anemia, CFC Syndrome (CFCS), Legius Syndrome, RASopathies
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies

NCT00388427
View directory record Official record
Conditions
Malignant Solid Tumour
Interventions
Dasatinib (BMS-354825), Cetuximab (Erbitux, C225)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jun 10, 2026, 2:10 PM EDT